Facebook
Twitter
Telegram
Report an ErrorBolt Biotherapeutics Balance Sheet 2011-2024 | BOLT
Annual Balance Sheet Bolt Biotherapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
9.41 M | 13.4 M | -3.03 M | 3.83 M | -24.6 M | -13.6 M | - | - | - | - | - | - | - |
Long Term Debt |
17.4 M | 20.2 M | 21.9 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.78 M | 2.39 M | 2.5 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 329 K | 85.6 M | 29.2 M | - | - | - | - | - | - | - |
Total Current Liabilities |
20.5 M | 23.1 M | 21.3 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
47 M | 56.3 M | 57.6 M | 46.2 M | 94.3 M | 31.9 M | - | - | - | - | - | - | - |
Deferred Revenue |
2.2 M | 1.99 M | 2.87 M | 1.5 M | 599 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-364 M | -295 M | -207 M | - | -47.7 M | -17.2 M | - | - | - | - | - | - | - |
Total Assets |
160 M | 228 M | 308 M | 46.5 M | 48.4 M | 16 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.8 M | 9.24 M | 27.4 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
113 M | 172 M | 250 M | 349 K | -45.8 M | -15.9 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
113 M | 172 M | 250 M | -105 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Bolt Biotherapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
16.7 M | 17.4 M | 18.2 M | 18.9 M | 19.6 M | 20.2 M | 20.9 M | 20.7 M | 21.3 M | 21.9 M | 22.5 M | 23.2 M | 9.06 M | 9.38 M | 9.38 M | 9.38 M | 9.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
38.7 M | 47 M | 47.1 M | 48.6 M | 48.5 M | 56.3 M | 57.1 M | 52.3 M | 54.4 M | 57.6 M | 58.6 M | 51.2 M | 21.4 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.91 M | 2.2 M | 1.94 M | 1.68 M | 1.6 M | 1.99 M | 3.17 M | 3.51 M | 3.45 M | 2.87 M | 5.21 M | 4.33 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-375 M | -364 M | -346 M | -330 M | -312 M | -295 M | -275 M | -253 M | -231 M | -207 M | -180 M | -156 M | -133 M | -108 M | -108 M | -108 M | -108 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
143 M | 160 M | 175 M | 191 M | 206 M | 228 M | 246 M | 260 M | 283 M | 308 M | 334 M | 347 M | 325 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.26 M | 10.8 M | 9.16 M | 13.5 M | 14.8 M | 9.24 M | 10.6 M | 22.6 M | 44 M | 27.4 M | 23.6 M | 58.3 M | 95.5 M | 5.54 M | 5.54 M | 5.54 M | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
104 M | 113 M | 128 M | 142 M | 158 M | 172 M | 188 M | 208 M | 228 M | 250 M | 275 M | 296 M | 303 M | 349 K | 349 K | 349 K | 349 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
104 M | 113 M | 128 M | 142 M | 158 M | 172 M | 188 M | 208 M | 228 M | 250 M | 275 M | 296 M | 303 M | -105 M | -105 M | -105 M | -105 M | -45.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency